BeyondSpring Chief Medical Officer to Present at Three Prominent Industry Conferences in May 2017

NEW YORK, May 08, 2017 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company’s Chief Medical Officer and Head of Business Development, Dr. Ramon Mohanlal, M.D., Ph.D., M.B.A., will present at the Evolution Summit in Miami, Chief Medical Officer Summit in Boston and Clinical Leader Forum in Philadelphia on May 8, 10 and 11, 2017, respectively.

Dr. Mohanlal will discuss the “Progression of Immunotherapy and its Impact on Cancer Research” as part of his presentation at the Evolution Summit at 5:15 p.m. ET at the Ritz-Carlton Coconut Grove, as well as join a panel on “Assessing and Creating Value and the Impact of Pricing Trends on R&D Strategies” at the Chief Medical Officer Summit at 9:30 a.m. ET at the Colonnade Hotel. Finally, Dr. Mohanlal will present on the importance of “Payer Perspective, Market Access and Patient Reported Outcomes” at this year’s Clinical Leader Forum at 3:15 p.m. ET at the Hilton Philadelphia City Avenue.

“It is an honor to speak at each of these prestigious conferences and present alongside some of the most exemplary leaders and pioneers in the healthcare and medical industry, opening up the dialogue around important topics that affect biopharma professionals everywhere,” said Dr. Mohanlal. “At BeyondSpring, these conversations are essential when it comes to continuing our work and growing our partnerships with other pharmaceutical professionals who have deep industry knowledge of the oncology space. Our team looks forward to capitalizing on these opportunities to help advance our lead asset, Plinabulin, which is in a Phase 3 trial as a direct anticancer agent in non-small cell lung cancer and Phase 2/3 trial for neutropenia prevention, to build toward its commercial success.”

Plinabulin, a novel small molecule that alters the tumor micro-environment and stimulates dendritic cell maturation and T-cell activation, has produced encouraging data regarding the mitigation of severe neutropenia, a common and potentially life-threatening adverse effect of Docetaxel. Plinabulin can be administered one hour after chemotherapy and has the potential to be a safe, cost-effective and convenient alternative with much less bone pain than G-CSF, the current standard of care for chemotherapy-induced neutropenia.

Plinabulin offers a same-day dosing advantage over G-CSF, which should be administered 24 hours after chemotherapy, per G-CSF label (next-day dosing), by which time significant damage to neutrophils has occurred. Additionally, Plinabulin has demonstrated a reduction in clinical sequelae associated with Docetaxel-induced neutropenia, including infections, sepsis, hospitalizations and the need for Docetaxel dose reductions.

The Evolution Summit is a forum that brings together leading drug development executives and solution providers, with the goal of providing an intimate environment in which attendees can take part in a focused discussion on key new drivers that are shaping drug development. The Chief Medical Officer Summit is an annual gathering of physicians where they exchange best practices in the advancement of drug development within the confines of the emerging biotech space. The Clinical Leader Forum is an event that’s focused on sponsor-CRO partnerships and issues that matter most to executives at small and midsize sponsor companies.

About BeyondSpring
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.

About Plinabulin
Studies on Plinabulin’s method of action indicate that Plinabulin activates GEF-H1, a guanine nucleotide exchange factor. GEF-H1 activates downstream transduction pathways leading to the activation of the protein c-Jun. Activated c-Jun enters the nucleus of dendritic cells to upregulate immune-related genes, which contributes to the up-regulation of a series of genes leading to dendritic cell maturation, T-cell activation and other effects that prevent neutropenia.

Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, the anticipated amount needed to finance the company’s future operations, unexpected results of clinical trials, delays or denial in regulatory approval process, our expectations regarding the potential safety, efficacy or clinical utility of our product candidates, or additional competition in the market. The forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Caitlin Kasunich / Amy Singh
KCSA Strategic Communications
212.896.1241 / 212.896.1207 /